Pacific Biosciences has named its executive management, board of directors, and scientific advisory board.
Hugh Martin joined the company in 2004 as CEO. He is also a company director. Previously, he was chairman, president, and CEO of ONI Systems, a high-speed optical telecommunications company that was sold to Ciena in 2002. He was also CEO in residence at VC company Kleiner Perkins Caufield and Byers, one of PacBio’s investors. Martin holds a BS in electrical engineering from Rutgers University.
PacBio co-founder Stephen Turner is the company’s chief technology officer and a company director. He holds a PhD from Cornell University, where he studied biomolecules in nano-fabricated fluidic structures with Harold Craighead, and a BS in physics, applied mathematics, and electrical engingeering from the University of Wisconsin Madison.
Michael Phillips is the company’s vice president for development. He joined PacBio in 2005 after he spent 20 years at Applied Biosystems in different capacities, which included roles in its genetic analysis, real-time PCR, and microarray R&D groups. He holds a BS in bacteriology from the University of California, Davis.
Martha Trela joined PacBio in 2006 as vice president of marketing. Previously, she was vice president of commercial marketing at Affymetrix, and worked at Applied Biosystems in different positions. She holds an MBA from the University of California, Berkeley, and a BS in biology from Stanford University.
Bruce Leisz came to PacBio last year as vice president of operations and program management. In the past, he was vice president of product R&D operations and interim senior vice president of global operations at Affymetrix. He also held positions in manufacturing and operations at GE Healthcare, Amersham Biosciences, and Molecular Dynamics. Leisz holds an MBA and a BS in mechanical engineering from the University of California, Berkeley.
Matthew Murphy is PacBio’s vice president of intellectual property and general counsel. Previously, he was vice president of legal affairs at Nanosys, and before that, vice president of intellectual property at Caliper Technologies, now Caliper Life Sciences. He holds a JD from the University of San Francisco and a BS in microbiology from the University of California Davis.
PacBio’s board of directors comprises Brook Byers, a partner at Kleiner Perkins Caufield and Byers; Bill Ericson, a general partner at MDS-Mohr Davidow Ventures; Michael Hunkapiller, a partner at Alloy Ventures and former general manager and president of Applied Biosystems; Sue Siegel, a general partner at Mohr Davidow Ventures and former president and director of Affymetrix; and David Singer, a partner of Maverick Capital and a founder and former CEO of Affymetrix.
The company’s scientific advisory board consists of Joseph Bonventre, a professor of medicine at Harvard Medical School and professor of health sciences and technology at the Massachusetts Institute of Technology; Harold Craighead, a professor of engineering and of applied and engineering physics at Cornell University and a co-founder of PacBio; David Haussler, a professor of biomolecular engineering at the University of California Santa Cruz; Chenming Calvin Hu, a professor of microelectronics in electrical engineering and computer sciences at the University of California, Berkeley; Kenneth Johnson, a professor of biochemistry at the University of Texas at Austin; Roger Kornberg, a professor of structural biology at Stanford University and 2006 Nobel Laureate; and Watt Webb, a professor of applied physics and engineering at Cornell University.
Carl Hull has been promoted to president and chief operating officer of Gen-Probe, effective March 1, the company said this week. He joined Gen-Probe a year ago as executive vice president and chief operating officer. Hull came to Gen-Probe from Applied Biosystems, where he was vice president and general manager of the sequence detection system and microarrays business unit. Hull has a BA in political science and international relations from the Johns Hopkins University and an MBA from the University of Chicago.
Nobel Laureate Joshua Lederberg died earlier this month at the age of 82. He was a professor and president emeritus at Rockefeller University. Lederberg received the Nobel Prize in 1958 at the age of 33 for his work in bacterial genetics. He shared the prize with Edward Tatum and George Beadle for their discovery that genes act by regulating specific chemical processes.